Last reviewed · How we verify
CVP
CVP is a chemotherapy regimen combining cyclophosphamide, vincristine, and prednisone to suppress cancer cell growth through multiple cytotoxic and immunosuppressive mechanisms.
CVP is a chemotherapy regimen combining cyclophosphamide, vincristine, and prednisone to suppress cancer cell growth through multiple cytotoxic and immunosuppressive mechanisms. Used for Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma, Hodgkin's lymphoma.
At a glance
| Generic name | CVP |
|---|---|
| Sponsor | SCRI Development Innovations, LLC |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
CVP is a combination chemotherapy regimen where cyclophosphamide acts as an alkylating agent, vincristine inhibits microtubule formation, and prednisone provides immunosuppression. This triple-agent approach targets rapidly dividing cells and is commonly used in hematologic malignancies. The regimen has been a standard treatment option for decades, particularly in lymphoid cancers.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Non-Hodgkin's lymphoma
- Hodgkin's lymphoma
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Infection
- Hemorrhage
Key clinical trials
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL (PHASE2)
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (PHASE3)
- Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy (PHASE2)
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma (PHASE3)
- Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (PHASE2)
- Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status
- Comparison of Noninvasive vs. Invasive Hemodynamic Measurements
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |